CTOT‐10 Study 2013.

Methods	Study design: parallel RCT Study duration: NS Mean duration of follow‐up: 40 weeks
Participants	Country: USA Setting: phase II, multi‐centre study First living or standard‐donor criteria kidney recipients; aged 18 to 65 y PRA: < 30% Epstein Barr virus seronegative: none Number: group 1 (6); group 2 (6); group 3 (7) Age: NS Sex (M/F): NS Exclusion criteria: extended‐criteria donor kidneys
Interventions	Group 1 (control) Alemtuzumab induction, tacrolimus maintenance Group 2 Alemtuzumab induction, belatacept maintenance Group 3 Basiliximab induction, 3 months taper of tacrolimus, belatacept maintenance Co‐interventions (all groups) Short‐term prednisone and maintenance mycophenolate mofetil 1g twice daily
Outcomes	Primary outcome: incidence of adverse events and serious adverse events
Notes	Sponsored by National Institute of Allergy and Infectious Diseases Halted prematurely (mean 40 weeks follow‐up) because four recipients had vascular thrombosis, three lost their grafts and there was a high incidence of acute rejection
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not described in abstracts
Allocation concealment (selection bias)	Unclear risk	Not described in abstracts
Blinding (performance bias and detection bias) All outcomes	Low risk	Open label
Incomplete outcome data (attrition bias) All outcomes	Low risk	Outcomes for all enrolled patients described in detail at time of study termination
Selective reporting (reporting bias)	Low risk	Adverse events reported fully in keeping with primary outcomes stated in protocol, though only in abstract form
Other bias	Unclear risk	Insufficient data published for reliable judgment